Activated lymphoid cells in human gliomas: Morphofuctional and cytochemical evidence

Rosanna Nano, Enrica Capelli, Monica Civallero, Lorenzo Lorusso, Fabio Argentina, Ennio Bonizzoni, Mauro Ceroni

Research output: Contribution to journalArticle

Abstract

To study defensive infiltrating cells, smear protection from 20 fresh gliomas and autologous normal peritumoural brain tissue, used as control, were analysed. May-Grunwald Giemsa staining and cytochemical reaction markers of cellular functions [acid phosphatase (AP), dihydrofolate reductase (DHFR), dipeptidilpeptidase (DAPIV) and serine esterase BLT-dependent (SE)], were employed to characterize the cells. The extent of the leukocytic infiltration and the percentage of activated lymphocytes ('hand mirror' shape lymphocytes: HMS; lymphocytes binding tumour: LBT) were also studied. In addition serum levels of T cell growth factor interleukin-2 (IL-2) and of the soluble IL-2 receptor (sIL-2R) were determined in the affected patients. In tumoural imprints, mostly in astrocytomas, we observed an increased percentage of DHFR and DAP IV positive lymphocytes, of HMS lymphocytes and of lymphocytes binding tumoral cells. Serum levels of IL-2 were significantly increased in all patients whilst sIL-2R levels were high only in glioblastoma. These findings indicate that in malignant gliomas there is stimulation of immune system as witnessed by the presence of activated cells inside tumour tissue and soluble activating factors in serum.

Original languageEnglish
Pages (from-to)107-111
Number of pages5
JournalAnticancer Research
Volume17
Issue number1 A
Publication statusPublished - 1997

Fingerprint

Glioma
Lymphocytes
Interleukin-2
Tetrahydrofolate Dehydrogenase
Interleukin-2 Receptors
Serum
Cytoprotection
Astrocytoma
Glioblastoma
Acid Phosphatase
Immune System
Neoplasms
Hand
Staining and Labeling
Brain

Keywords

  • Activated cells
  • Cytochemistry
  • Cytokines
  • Glioma
  • Immunoassay

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nano, R., Capelli, E., Civallero, M., Lorusso, L., Argentina, F., Bonizzoni, E., & Ceroni, M. (1997). Activated lymphoid cells in human gliomas: Morphofuctional and cytochemical evidence. Anticancer Research, 17(1 A), 107-111.

Activated lymphoid cells in human gliomas : Morphofuctional and cytochemical evidence. / Nano, Rosanna; Capelli, Enrica; Civallero, Monica; Lorusso, Lorenzo; Argentina, Fabio; Bonizzoni, Ennio; Ceroni, Mauro.

In: Anticancer Research, Vol. 17, No. 1 A, 1997, p. 107-111.

Research output: Contribution to journalArticle

Nano, R, Capelli, E, Civallero, M, Lorusso, L, Argentina, F, Bonizzoni, E & Ceroni, M 1997, 'Activated lymphoid cells in human gliomas: Morphofuctional and cytochemical evidence', Anticancer Research, vol. 17, no. 1 A, pp. 107-111.
Nano R, Capelli E, Civallero M, Lorusso L, Argentina F, Bonizzoni E et al. Activated lymphoid cells in human gliomas: Morphofuctional and cytochemical evidence. Anticancer Research. 1997;17(1 A):107-111.
Nano, Rosanna ; Capelli, Enrica ; Civallero, Monica ; Lorusso, Lorenzo ; Argentina, Fabio ; Bonizzoni, Ennio ; Ceroni, Mauro. / Activated lymphoid cells in human gliomas : Morphofuctional and cytochemical evidence. In: Anticancer Research. 1997 ; Vol. 17, No. 1 A. pp. 107-111.
@article{edeb79fa18a146bd8bc5313325e2fc1a,
title = "Activated lymphoid cells in human gliomas: Morphofuctional and cytochemical evidence",
abstract = "To study defensive infiltrating cells, smear protection from 20 fresh gliomas and autologous normal peritumoural brain tissue, used as control, were analysed. May-Grunwald Giemsa staining and cytochemical reaction markers of cellular functions [acid phosphatase (AP), dihydrofolate reductase (DHFR), dipeptidilpeptidase (DAPIV) and serine esterase BLT-dependent (SE)], were employed to characterize the cells. The extent of the leukocytic infiltration and the percentage of activated lymphocytes ('hand mirror' shape lymphocytes: HMS; lymphocytes binding tumour: LBT) were also studied. In addition serum levels of T cell growth factor interleukin-2 (IL-2) and of the soluble IL-2 receptor (sIL-2R) were determined in the affected patients. In tumoural imprints, mostly in astrocytomas, we observed an increased percentage of DHFR and DAP IV positive lymphocytes, of HMS lymphocytes and of lymphocytes binding tumoral cells. Serum levels of IL-2 were significantly increased in all patients whilst sIL-2R levels were high only in glioblastoma. These findings indicate that in malignant gliomas there is stimulation of immune system as witnessed by the presence of activated cells inside tumour tissue and soluble activating factors in serum.",
keywords = "Activated cells, Cytochemistry, Cytokines, Glioma, Immunoassay",
author = "Rosanna Nano and Enrica Capelli and Monica Civallero and Lorenzo Lorusso and Fabio Argentina and Ennio Bonizzoni and Mauro Ceroni",
year = "1997",
language = "English",
volume = "17",
pages = "107--111",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 A",

}

TY - JOUR

T1 - Activated lymphoid cells in human gliomas

T2 - Morphofuctional and cytochemical evidence

AU - Nano, Rosanna

AU - Capelli, Enrica

AU - Civallero, Monica

AU - Lorusso, Lorenzo

AU - Argentina, Fabio

AU - Bonizzoni, Ennio

AU - Ceroni, Mauro

PY - 1997

Y1 - 1997

N2 - To study defensive infiltrating cells, smear protection from 20 fresh gliomas and autologous normal peritumoural brain tissue, used as control, were analysed. May-Grunwald Giemsa staining and cytochemical reaction markers of cellular functions [acid phosphatase (AP), dihydrofolate reductase (DHFR), dipeptidilpeptidase (DAPIV) and serine esterase BLT-dependent (SE)], were employed to characterize the cells. The extent of the leukocytic infiltration and the percentage of activated lymphocytes ('hand mirror' shape lymphocytes: HMS; lymphocytes binding tumour: LBT) were also studied. In addition serum levels of T cell growth factor interleukin-2 (IL-2) and of the soluble IL-2 receptor (sIL-2R) were determined in the affected patients. In tumoural imprints, mostly in astrocytomas, we observed an increased percentage of DHFR and DAP IV positive lymphocytes, of HMS lymphocytes and of lymphocytes binding tumoral cells. Serum levels of IL-2 were significantly increased in all patients whilst sIL-2R levels were high only in glioblastoma. These findings indicate that in malignant gliomas there is stimulation of immune system as witnessed by the presence of activated cells inside tumour tissue and soluble activating factors in serum.

AB - To study defensive infiltrating cells, smear protection from 20 fresh gliomas and autologous normal peritumoural brain tissue, used as control, were analysed. May-Grunwald Giemsa staining and cytochemical reaction markers of cellular functions [acid phosphatase (AP), dihydrofolate reductase (DHFR), dipeptidilpeptidase (DAPIV) and serine esterase BLT-dependent (SE)], were employed to characterize the cells. The extent of the leukocytic infiltration and the percentage of activated lymphocytes ('hand mirror' shape lymphocytes: HMS; lymphocytes binding tumour: LBT) were also studied. In addition serum levels of T cell growth factor interleukin-2 (IL-2) and of the soluble IL-2 receptor (sIL-2R) were determined in the affected patients. In tumoural imprints, mostly in astrocytomas, we observed an increased percentage of DHFR and DAP IV positive lymphocytes, of HMS lymphocytes and of lymphocytes binding tumoral cells. Serum levels of IL-2 were significantly increased in all patients whilst sIL-2R levels were high only in glioblastoma. These findings indicate that in malignant gliomas there is stimulation of immune system as witnessed by the presence of activated cells inside tumour tissue and soluble activating factors in serum.

KW - Activated cells

KW - Cytochemistry

KW - Cytokines

KW - Glioma

KW - Immunoassay

UR - http://www.scopus.com/inward/record.url?scp=0031050930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031050930&partnerID=8YFLogxK

M3 - Article

C2 - 9066638

AN - SCOPUS:0031050930

VL - 17

SP - 107

EP - 111

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 A

ER -